Walking the Talk With Our Money: HIVAIDS

1
Walking the Talk With Our MoneyHIV/AIDS

• Pat Zerega, Director
• Corporate Social Responsibility, ELCA
• 9625 Perry Highway
• Pittsburgh PA 15237
• 412.367.7575
• patricia.zerega_at_elca.org

2
We impact the world in a variety of ways our
presence our leadership our actions our
charityWe also impact the world through how we
use our money.
3
When we speak of using our money in light of our
faith, we often hear

• I have so little money to deal with
• Id like to look at that, but I only have mutual
  funds
• I need a better return
• I have so little time to understand this

4
Lets spend some time looking at the spectrum of
ways one might walk the talk when it comes to our
money.
5
Are we environmentally efficient?
(www.elca.org/advocacy/environment/envaudit.pdf) D
o we purchase fairly traded products? What do we
consider in where to purchase or who we hire?
6
Do we not invest in certain items? Do we apply
screens to our investments? Do we use mutual
funds that screen out certain investments?
7

• Can our money be life giving?
• Community loan fund
• Micro credit funds
• Companies we feel do good

8
Shareholder Advocacy

• Sometimes we can encourage more responsible
  levels of corporate citizenship
• Through corporate dialogues
• Through filing shareholder proposals
• Through attending annual meetings
• Through grass roots advocacy

9
Current Shareholder Work

• ISSUES
• Environment
• Human Rights
• Sustainability
• Access to Pharmaceuticals
• Access to Capital
• Violence

10
HIV/AIDS
11
ELCA Shareholder Proposal

• - Policy Report on Ethical Criteria for
  Extension of Prescription Drug Patents 2002

12
Policy Report on Ethical Criteria for Extension
of Prescription Drug Patents 2002

• BE IT RESOLVED, Shareholders request the Board of
  Directors to develop ethical criteria for the
  extension of patents on prescription drugs and to
  issue a report on the implementation of such
  criteria. The Report, prepared at reasonable cost
  and omitting proprietary information, will be
  made available to all shareholders by September
  2003.

13
ELCA Shareholder Proposal

• - Report Related to Global HIV/AIDS-TB-Malaria
  Pandemics Pharmaceutical Company 2003-2004

14
Report Related to Global HIV/AIDS-TB-Malaria
Pandemics Pharmaceutical Company

• Resolved, Shareholders request that our Board
  review the economic effects of the HIV/AIDS,
  tuberculosis and malaria pandemics on the
  company's business strategy, and its initiatives
  to date, and report to shareholders within six
  months following the 2005 annual meeting. This
  report, developed at reasonable costs and
  omitting proprietary information, will identify
  the impacts of these pandemics on the company.

15
ELCA Shareholder Proposal

• - Report Related to Global HIV/AIDS-TB-Malaria
  Pandemics Non-Pharmaceutical Company 2004-2007

16
Report Related to Global HIV/AIDS-TB-Malaria
Pandemics Non-Pharmaceutical Company

• Resolved, Shareholders request that our Board
  review the economic effects of the HIV/AIDS,
  tuberculosis and malaria pandemics on the
  company's business strategy, and its initiatives
  to date, and report to shareholders within six
  (6) months following the 2005 annual meeting.
  This report, developed at reasonable costs and
  omitting proprietary information, will identify
  the impacts of these pandemics on the company.

17
Proxy Voting

• Annually a proxy statement is sent out from the
  company asking its shareholders to vote. Items
  vary from boards of directors endorsements to
  shareholder resolutions. Read these carefully and
  see how the issues line up with your values. For
  some ideas on how the church looks at these see
  www.elca.org/corporate and read our issue papers.

18
(No Transcript)
19
Join the e-Advocacy Network www.elca.org/advocac
y

20
Receive alerts from the Ecumenical Advocacy
Alliance

21
Ecumenical Advocacy Alliance

22
Ecumenical Advocacy Alliance

23
Ecumenical Advocacy Alliance postcard campaign

24
Sign up for the Shareholders Network
www.elca.org/corporate